• Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product’ assets with a potential of over €5 billion peak sales
• Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapies
• Enhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 years
• Ambition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of Dupixent and Vaccines

 Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.

Focusing on its unprecedented portfolio of 12 new molecular entities with blockbuster potential, including multiple late-stage assets, the company will be prioritizing development and leveraging its leadership in immunology across all other therapeutic areas. Sanofi will also share its ambitions to break efficacy ceilings and expand into new indications, generating a steady flow of predominantly wholly-owned new assets.

The company will continue to serve more patients with a combination of strong growth from existing assets and a steady stream of potential blockbuster launches:

• Pharma assets - Recently launched and future pharma assets are expected to generate over €10 billion of annual sales by 2030, driven by late-stage pipeline assets such as amlitelimab, frexalimab, itepekimab, and tolebrutinib, as well as recently launched products including ALTUVIIIO®, Sarclisa®, and Tzield®.
• Dupixent^® - Expected to continue its strong performance and to deliver a low double-digit net sales growth CAGR from 2023 to 2030, supported by expected new indications such as chronic obstructive pulmonary disease (COPD) as well as greater penetration in approved indications.
• Vaccines - Sanofi reiterates its expectation to generate over €10 billion of annual sales by 2030, including the recent launch of Beyfortus®.
  
  

Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.

Houman Ashrafian, Head of Research and Development, Sanofi

“Today we show how our decision to strategically increase our focus on R&D will unlock our pipeline’s full potential as we prioritize potential first- or best-in-class assets to deliver innovative medicines to patients. With an unprecedented number of potential blockbuster assets in our pipeline, we will showcase how we become a development-driven, tech-powered biopharma company, committed to serving patients and accelerating growth. We are in a privileged position today with many very promising assets in mid- and late-stage development. We believe in our capacity to improve outcomes for patients globally, while bringing innovative new medicines to market and strengthening our leadership in immunology and neuro-inflammation.”

Paul Hudson, Chief Executive Officer, Sanofi

“Building on our successful recent launches, we are making decisive choices to deliver breakthrough medicines and long-term value for all of our stakeholders. We are confident in our current product portfolio and the strength of our pipeline to deliver sustainable growth through 2030 and beyond. I could not be prouder of the progress we have made over the past three years, and I am looking forward to sharing further updates as our key assets pass new milestones toward their market launch and as we turn Sanofi into an immunology powerhouse.”

Highlighted key programs

Sanofi shares insights into the development status and target indications of its pipeline of 12 potential blockbuster assets in immunology and vaccines. This includes its three ‘pipeline-in-a-product’ assets, amlitelimab, frexalimab and SAR441566 (Oral TNFR1si), each with a peak sales potential of over €5 billion, as well as treatments for multiple sclerosis (tolebrutinib), asthma (lunsekimig, rilzabrutinib), inflamatory bowel disease (Anti-TL1A), atopic dermatitis (IRAK4 degrader), and COPD (itepekimab). Additional potential blockbusters include vaccines against acne, extraintestinal pathogenic E. coli, and RSV in older adults.

The company also demonstrates strong proof points of its progress in increasing R&D productivity, notably by continuously evolving its R&D engine, unlocking the power of its data and leveraging AI at scale to inform portfolio decisions. Additionally, Sanofi presents the actions taken to reflect the group’s sustainability roadmap across its development pipeline.